Jitendra "Jitty" Malik

Jitendra "Jitty" Malik is a patent litigation partner at Katten Muchin Rosenman LLP with a practice concentrated on the pharmaceutical and life sciences sectors. Holding a Ph.D. in Polymer Science and Engineering, his work is deeply informed by his technical background in chemistry, biochemistry, and polymer science. Dr. Malik's practice focuses significantly on litigation related to the drug approval process, including extensive experience with the Hatch-Waxman Act and the Biologics Price Competition and Innovation Act (BPCIA).

While the provided data shows a single appearance for a plaintiff (Apotex Inc.), Dr. Malik is frequently recognized for his work representing defendants, particularly generic pharmaceutical companies in Abbreviated New Drug Application (ANDA) litigation. His broader practice includes serving as lead trial counsel in several notable district court cases involving patents for treatments related to multiple myeloma and metastatic colorectal cancer. He represents clients in patent disputes across the country.

Dr. Malik joined Katten's Charlotte office as a partner in 2018, having previously practiced at Alston & Bird LLP. In addition to his district court trial work, he has substantial experience in post-grant proceedings before the Patent Trial and Appeal Board (PTAB), including inter partes review (IPR), post-grant review (PGR), and reexaminations. The tracked case, Apotex Inc. v. Soleno Therapeutics Inc., is a post-grant review proceeding before the PTAB.

According to his firm biography, Dr. Malik earned his J.D. from Wake Forest University School of Law.